Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Blood (2023) 142 (Supplement 1): 6248.

https://doi.org/10.1182/blood-2023-179200

Published: 2023

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138412

Published: 2020

Journal Articles

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Blood (2019) 134 (Supplement_1): 3007.

https://doi.org/10.1182/blood-2019-126671

Published: 2019

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Roxana Schaab, Christina Ganster, PhD, Sascha Dierks, PhD, Katayoon Shirneshan, PhD, Marc Talló Parra, Roman Martin, PhD, Ulrich Germing, Uwe Platzbecker, MD, Frank Lange, MD, Nicolaus Kroeger, MD, Konstanze Döhner, MD, Bertram Glass, MD, Maike Nickelsen, MD, Reingard Stuhlmann, MD, Lorenz H. Truemper, MD, Julie Schanz, MD, Ulrike Bacher, MD, Detlef Haase, MD

Blood (2016) 128 (22): 2001.

https://doi.org/10.1182/blood.V128.22.2001.2001

Published: 2016

Journal Articles

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

Norbert Schmitz, MD PhD, Maike Nickelsen, MD, Marita Ziepert, PhD, Mathias Haenel, MD, Andreas Viardot, MD, Martin H. Dreyling, MD PhD, Peter Borchmann, MD, Carsten Bokemeyer, MD, Christian Peschel, MD, Hans-Heinrich Wolf, MD, Rolf Mahlberg, MD, Michael Pfreundschuh, MD, Bertram Glass, MD

Blood (2015) 126 (23): 474.

https://doi.org/10.1182/blood.V126.23.474.474

Published: 2015

Journal Articles

Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma

Kerry J. Savage, MDMSc, Samira Zeynalova, PhD, Roopesh R. Kansara, MD, Maike Nickelsen, MD, Diego Villa, MDMPH, Laurie H. Sehn, MDMPH, Marita Ziepert, David W. Scott, MBChB, PhD, Michael Pfreundschuh, MD PhD, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Bertram Glass, MD, Markus Loeffler, Prof MDPhD, Norbert Schmitz

Blood (2014) 124 (21): 394.

https://doi.org/10.1182/blood.V124.21.394.394

Published: 2014

Journal Articles

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Bertram Glass, MD, Anke Goerlitz, Sebastian Pfeiffer, Maike Nickelsen, MD, Andreas Huettmann, MD, Justin Hasenkamp, MD, Lorenz H. Truemper, MD PhD, Martin Dreyling, Michael G Kiehl, MD, Hans Salwender, MD, Norbert Schmitz, MD

Blood (2014) 124 (21): 1754.

https://doi.org/10.1182/blood.V124.21.1754.1754

Published: 2014

Journal Articles

Comparison Of R-CHOP14 and R-CHOEP14 As First Line Treatment In Young Patients With High-Risk (aaIPI 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): A Joint Analysis Of Two Prospective Phase III Randomized Trials Conducted By The Fondazione Italiana Linfomi (FIL) and The German High-Grade Lymphoma Study Group (DSHNHL)

Umberto Vitolo, MD, Marita Ziepert, Bertram Glass, Bettina Altmann, Annalisa Chiappella, Andrea Evangelista, Giovannino Ciccone, Pier Luigi Zinzani, Maike Nickelsen, Markus Loeffler, Maurizio Martelli, MD, Norbert Schmitz

Blood (2013) 122 (21): 4341.

https://doi.org/10.1182/blood.V122.21.4341.4341

Published: 2013

Journal Articles

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

Norbert Schmitz, Lorenz Trümper, Marita Ziepert, Maike Nickelsen, Anthony D. Ho, Bernd Metzner, Norma Peter, Markus Loeffler, Andreas Rosenwald, Michael Pfreundschuh

Blood (2010) 116 (18): 3418–3425.

https://doi.org/10.1182/blood-2010-02-270785

Published: 2010

Includes: Supplemental data

Journal Articles

Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.

Bertram Glass, MD, PhD, Andrea Borgerding, Marita Ziepert, Maike Nickelsen, Markus Loeffler, Prof., Michael Pfreundschuh, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3714.

https://doi.org/10.1182/blood.V114.22.3714.3714

Published: 2009

Journal Articles

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Matthias Haenel, Peter Borchmann, PD, Dr., Andreas Viardot, Christina Nickenig, Martin Bentz, MD, Christian Peschel, MD, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Bertram Glass, MD, PhD

Blood (2009) 114 (22): 404.

https://doi.org/10.1182/blood.V114.22.404.404

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Bertram Glass, MD, PhD, Justin Hasenkamp, MD, Anke Goerlitz, Peter Dreger, Joerg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, Lorenz H. Truemper, MD, Norbert Schmitz

Blood (2009) 114 (22): 3379.

https://doi.org/10.1182/blood.V114.22.3379.3379

Published: 2009

Journal Articles

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Anke Görlitz, Peter Dreger, MD, Jörg Schubert, MD, Gerald Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD, PhD

Blood (2008) 112 (11): 1974.

https://doi.org/10.1182/blood.V112.11.1974.1974

Published: 2008

Journal Articles

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Maike Nickelsen, MD, Carmen Canals, Sr., Charalampia Kyriakou, MD, PhD, Norbert Schmitz, MD, PhD, Agnes Buzyn, MD, Monika Engelhardt, MD, PhD, Bertram Glass, MD, PhD, Eulogio Conde, MD, Armando Lopez-Guillermo, MD, Gerard Socie, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 974.

https://doi.org/10.1182/blood.V112.11.974.974

Published: 2008

Journal Articles

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Maike Nickelsen, MD, Carmen Canals, Sr., MD, Norbert Schmitz, MD, PhD, Charalampia Kyriakou, MD, PhD, Monika Engelhardt, MD, PhD, Thomas Relander, MD, Werner Linkesch, MD, PhD, Vladimir Koza, MD, Giovanna Meloni, MD, Armando Lopez-Guillermo, MD, Karel Indrac, MD, Dolores Caballero, MD, Hannes Wandt, MD, PhD, Niklas Theorin, MD, Bertram Glass, MD, PhD, Anna Sureda, MD, PhD

Blood (2008) 112 (11): 774.

https://doi.org/10.1182/blood.V112.11.774.774

Published: 2008

Journal Articles

Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.

Michael Rieger, MD, Mathias Witzens-Harig, MD, Manfred Hensel, MD, Baerbel Seyfarth, MD, Maike Nickelsen, MD, Michael Kneba, MD, Norbert Schmitz, MD, Anthony D. Ho, MD, Peter Dreger, MD

Blood (2007) 110 (11): 5106.

https://doi.org/10.1182/blood.V110.11.5106.5106

Published: 2007

Journal Articles

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Bertram Glass, MD, Justin Hasenkamp, MD, Peter Dreger, MD, Martin Gramatzki, MD, Joerg Schubert, MD, Gerald G. Wulf, MD, Maike Nickelsen, MD, Lorenz H. Truemper, MD, Norbert Schmitz, MD

Blood (2007) 110 (11): 3043.

https://doi.org/10.1182/blood.V110.11.3043.3043

Published: 2007

Journal Articles

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Viola Poeschel, MD, Maike Nickelsen, M.D., Mathias Hanel, M.D., Stephan Kremers, M.D., Swen Wessendorf, M.D., Hartmut Eimermacher, M.D., Norma Peter, M.D., Michael Wenger, M.D., Marcel Reiser, M.D., Norbert Schmitz, M.D., Michael Pfreundschuh, M.D.

Blood (2006) 108 (11): 2738.

https://doi.org/10.1182/blood.V108.11.2738.2738

Published: 2006

NARROW

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group

Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma

Combination of Lenalidomide and R-DHAP for Treatment of Relapsed and Refractory Aggressive B-NHL

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.

Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation

Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.

Intermediate Intensity Conditioning Followed by Allogeneic Peripheral Blood Stem Cell Transplantion for Treatment of High Risk Relapse of Aggressive Lymphoma. Interim Analysis of the DSHNHL R3 Study.

Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only